FDA Faces Internal Changes and Challenges - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Faces Internal Changes and Challenges
Food-safety, transparency, and counterfeit-drug growth will tax agency resources.


Pharmaceutical Technology
Volume 35, Issue 2, pp. 26-30

Deputy departs

At last year's House Oversight Committee hearings on J&J's manufacturing problems and recalls, FDA was represented by Principal Deputy Commissioner Joshua Sharfstein. He won plaudits for having command of the issues and for answering questions directly, a performance that benefited from earlier experience on Capitol Hill as an aide to Rep. Henry Waxman (D-CA). Now someone else at FDA will have to fill the hot seat at Congressional hearings following Sharfstein's surprise departure from the agency last month.

Sharfstein was lured away by an offer to head Maryland's health department, a move that capitalizes on his public health roots as Baltimore's health commissioner before coming to FDA. In moving to the state agency, Sharfstein will manage a $7-billion budget—which is much bigger than FDA's. He also will be involved with implementing the many healthcare-reform programs and policies that require state involvement, including an expansion in Medicaid and formation of new health insurance exchanges.

At FDA, Sharfstein helped to engineer a get-tough compliance policy designed to eliminate perceptions that FDA had become too cozy with industry. This stronger enforcement stance has produced more Warning Letters that cite manufacturing and marketing violations and more criminal investigations, trends that are likely to continue. He also was involved in strengthening FDA's medical-device regulatory process, a high-profile exercise that is still ongoing, and he was a strong advocate for ensuring drug safety and establishing tight curbs on the use of more risky medicines, such as GlaxoSmithKline's diabetes drug Avandia (rosiglitazone).

Hamburg is using Sharfstein's departure as an opportunity to re-examine the agency's top management structure. Previous commissioners have tried various senior-staff arrangements, with deputy commissioners, chiefs of staff, and special assistants, and Hamburg may move away from the current one-deputy plan.

Counselor to the Commissioner John Taylor is filling Sharfstein's shoes while the commissioner weighs her options, and he is expected to assume a more visible role at the agency in the future. Taylor has had a long career at FDA in legal, enforcement, and regulatory affairs positions under several FDA commissioners during both Democratic and Republican administrations. He rose to be associate commissioner for regulatory affairs from 2002 to 2005 and then served brief stints at Abbott Laboratories and with the Biotechnology Industry Organization. Taylor returned to FDA in 2009 to be Hamburg's top legal advisor, and the commissioner might well prefer to have such a seasoned enforcement official represent FDA before Congressional committees probing enforcement and safety issues.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here